Back to top
more

MacroGenics (MGNX)

(Delayed Data from NSDQ)

$15.61 USD

15.61
793,163

-0.46 (-2.86%)

Updated Apr 19, 2024 03:59 PM ET

After-Market: $15.61 0.00 (0.00%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MGNX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

MacroGenics, Inc. [MGNX]

Reports for Purchase

Showing records 101 - 120 ( 360 total )

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 101

01/21/2020

Company Report

Pages: 6

Marge Marching to Market

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 102

01/09/2020

Daily Note

Pages: 18

2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 103

12/20/2019

Daily Note

Pages: 5

Marge, Now in the Hands of the Agency, But We Find the Likely Initiation of the PODIUM -301/304 Studies More Newsworthy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 104

12/13/2019

Daily Note

Pages: 6

Detailed Look at SOPHIA Interim 2 Analysis at SABCS

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 105

12/13/2019

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 106

12/13/2019

Daily Note

Pages: 11

HEALTHCARE-The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 107

12/12/2019

Company Report

Pages: 5

Marge-Doublet Appears to Be Numerically Comparable to Tucatinib-Triplet

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 108

12/12/2019

Industry Report

Pages: 47

ASH 2019: Hangover: Covered Companies Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 109

12/10/2019

Daily Note

Pages: 3

Flotetuzumab at ASH: Reinforcing the Case for TME Based Sensitivity in Primary Refractory AML

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 110

12/06/2019

Industry Report

Pages: 12

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 111

11/29/2019

Industry Report

Pages: 12

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 112

11/15/2019

Daily Note

Pages: 35

2019 Abstract Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 113

11/07/2019

Company Report

Pages: 8

Handwringing Over SOPHIA Continues; But Margetuximab Nearly Fully Discounted at Current Levels

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 114

11/07/2019

Company Report

Pages: 8

And we’ll all Flote on at ASH

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 115

11/06/2019

Daily Note

Pages: 3

Flotetuzumab; Holding up in Primary Refractory AML

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 116

10/23/2019

Company Report

Pages: 9

Competitive Landscape the Bigger Headwind vs. the In-Line Read From the Second Interim OS; Target Lowered to $18

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 117

10/23/2019

Company Report

Pages: 8

Decreasing PT as Second Interim SOPHIA Analysis Disappoints

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 118

10/23/2019

Daily Note

Pages: 10

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 119

10/03/2019

Industry Report

Pages: 30

Biotechnology - ESMO 2019 Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 120

10/01/2019

Daily Note

Pages: 4

Mature GC data points to compelling clinical benefit

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party